The United Laboratories International Holdings Limited (3933) announced that Roxithromycin Capsules (150mg) developed by its wholly-owned subsidiary, Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, have successfully passed the consistency evaluation of quality and efficacy for generic drugs, as approved by China National Medical Products Administration.

Roxithromycin Capsules are second-generation macrolide antibiotics noted for acid stability, broad antibacterial spectrum, strong tissue penetration, and a relatively low incidence of adverse reactions. They are indicated for infections of the ear, nose, throat, respiratory tract, skin and soft tissues, and the genitourinary tract caused by pathogenic bacteria susceptible to roxithromycin. They are categorized as Category B in the National Medical Insurance Drug List (2025 Edition). According to the announcement, the United Laboratories is the first enterprise to obtain this consistency evaluation approval for the Roxithromycin Capsules dosage form.

The board of directors stated that this approval further strengthens the group’s position in the anti-infective field and highlighted the company’s continued commitment to research and development of new products, aiming to generate greater value for both the company and its shareholders.